Tag: Glucagon-Like Peptide-1
-
When the Most Common Liver Disease Became Treatable
MASLD can no longer be treated as a low-priority diagnosis of exclusion. It is a screenable, stratifiable, and increasingly treatable disease.
-
The Quiet Toll Visceral Fat Takes on the Brain
Sustained visceral fat loss, independent of total weight change, is associated with attenuated brain atrophy and preserved cognitive performance years later.
-
The End of Creams and the Beginning of Clocks
The anti-aging era gave us creams and promises. The longevity era offers the scientific tools to understand, measure, and meaningfully modify aging.
-
Feeding the Microbes That Shrink Your Deepest Fat
Feeding your inner fat burner becomes less a narrative of individual willpower and more a systems-level partnership with trillions of microbial co-inhabitants.
-
When the Peptide Promise Outpaces the Proof
Peptides are not inherently good. They are not inherently bad. They are complex biological signals operating in complex physiological contexts.
-
How GLP-1 Receptor Agonists Transformed the Treatment of Obesity and Diabetes
The GLP-1 receptor agonist and multi-receptor agonist class represents the most important pharmacological advance in metabolic medicine in the 21st century.
-
Therapeutic Peptides as Precision Medicine for Longevity, Metabolism, and Tissue Repair
Therapeutic peptides, targeting the molecular hallmarks of ageing with a precision impossible for small molecules, are positioned to become foundational tools in preventive medicine.